Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
Ulrich Gatzemeier, Frances A. Shepherd, Thierry Le Chevalier et al. · European Journal of Cancer · 1996
Cited by 241 works. doi:10.1016/0959-8049(95)00444-0
Authors
- Ulrich Gatzemeier
- Frances A. Shepherd
- Thierry Le Chevalier
- Patrick Weynants
- Brian Cottier
- Harry J.M. Groen
- Renzo Rosso
- Karin V. Mattson
- H. Cortés-Funes
- Maurizio Tonato
- Ronald L. Burkes
- Maya Gottfried
- Maurizio Voi
References
- Cancer: Principles and Practice of Oncology.
- WHO Handbook for Reporting Results of Cancer Treatment
- Manual for Staging of Cancer
- [Cancer of the lung].
- Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
- Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
- Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
- Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
- Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer